Exact Sciences Corp. inked a licensing deal with Hologic Inc. that will see it integrate one of its colorectal cancer screening technologies with the Bedford, Mass.-based women’s health firm’s Invader molecular detection platform.
Madison, Wis.-based Exact Sciences, which moved from Marlborough, Mass., to the Badger State in June, said it plans to couple the digital polymerase chain reaction technology it’s already licensed from Johns Hopkins University with the Invader molecular detection platform. Invader is made by Hologic subsidiary Third Wave Technologies.
The end goal is a stool-based DNA test for colorectal cancer; Exact claims to be the sole player in that market, which it estimated as being worth $1 billion.
